Exchange Traded Concepts LLC Has $10 Million Stock Position in Eli Lilly and Company $LLY

Exchange Traded Concepts LLC cut its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 48.1% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 13,103 shares of the company’s stock after selling 12,137 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Eli Lilly and Company were worth $9,998,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Abner Herrman & Brock LLC grew its holdings in shares of Eli Lilly and Company by 0.5% during the 3rd quarter. Abner Herrman & Brock LLC now owns 27,800 shares of the company’s stock valued at $21,212,000 after acquiring an additional 152 shares in the last quarter. AA Financial Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 18.2% during the 3rd quarter. AA Financial Advisors LLC now owns 4,052 shares of the company’s stock valued at $3,092,000 after buying an additional 625 shares during the last quarter. Northwest Wealth Management LLC grew its stake in shares of Eli Lilly and Company by 4.1% in the 3rd quarter. Northwest Wealth Management LLC now owns 886 shares of the company’s stock valued at $676,000 after buying an additional 35 shares in the last quarter. Parkwoods Wealth Partners LLC increased its holdings in Eli Lilly and Company by 7.0% in the third quarter. Parkwoods Wealth Partners LLC now owns 752 shares of the company’s stock worth $574,000 after buying an additional 49 shares during the last quarter. Finally, Bridge Creek Capital Management LLC raised its position in Eli Lilly and Company by 0.8% during the third quarter. Bridge Creek Capital Management LLC now owns 1,970 shares of the company’s stock valued at $1,503,000 after acquiring an additional 15 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have recently weighed in on LLY. HSBC restated a “hold” rating and set a $1,070.00 price target on shares of Eli Lilly and Company in a report on Wednesday, December 10th. JPMorgan Chase & Co. raised their target price on Eli Lilly and Company from $1,050.00 to $1,150.00 and gave the company an “overweight” rating in a report on Tuesday, November 18th. Sanford C. Bernstein reiterated an “outperform” rating on shares of Eli Lilly and Company in a research note on Friday. Leerink Partners reissued an “outperform” rating on shares of Eli Lilly and Company in a research note on Thursday, December 18th. Finally, Daiwa Capital Markets set a $1,230.00 target price on Eli Lilly and Company and gave the stock a “buy” rating in a research report on Tuesday, December 16th. Four research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,155.36.

Eli Lilly and Company Stock Down 0.5%

Shares of LLY stock opened at $1,070.80 on Wednesday. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,111.99. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. The firm has a market cap of $1.01 trillion, a PE ratio of 52.39, a price-to-earnings-growth ratio of 1.09 and a beta of 0.37. The stock has a 50 day moving average of $971.08 and a 200-day moving average of $835.68.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The firm had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. During the same period in the prior year, the firm earned $1.18 EPS. The business’s revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, equities analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be paid a dividend of $1.73 per share. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, February 13th. Eli Lilly and Company’s dividend payout ratio is presently 29.35%.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Zacks raised quarterly and full‑year EPS estimates for LLY, reflecting stronger-than-expected GLP-1 and franchise momentum which supports earnings upside. Zacks raises LLY estimates
• Positive Sentiment: Forbes outlines three possible catalysts that could trigger an LLY rally (pipeline readouts, successful oral GLP‑1 launch execution and M&A/partnerships), providing a roadmap for upside if Lilly executes. 3 Catalysts That Can Start An Eli Lilly Stock Rally
• Positive Sentiment: High‑profile bullish commentary (e.g., Jim Cramer) and positive Phase‑3/clinical data updates (breast cancer, EMBER‑3 imlunestrant results) keep long‑term conviction intact for growth beyond obesity drugs. Jim Cramer on Lilly
• Positive Sentiment: Broker support remains: Bank of America and others maintain Buy/overweight views and some firms have raised price targets based on eventual realization of obesity‑drug earnings. This provides analyst backing for potential rebounds. BofA maintains Buy on Eli Lilly
• Neutral Sentiment: Sector rotation into healthcare/XLV increases passive demand for LLY (it’s a large ETF holding), supporting structural investor interest even amid short‑term volatility. Sector Rotation: 2 Smart Money Moves for 2026
• Neutral Sentiment: Deal speculation (reported meetings with Abivax/French officials) and ongoing partnership chatter could be upside optionality but are early-stage and uncertain. Abivax soars on Lilly meeting report
• Negative Sentiment: Major near-term headwind: the FDA approved Novo Nordisk’s oral Wegovy pill — the first daily oral obesity drug — giving Novo a first‑mover advantage that could pressure Lilly’s orforglipron launch timing/market share and is driving the stock pullback. Novo Nordisk weight-loss drug wins US approval as a daily pill
• Negative Sentiment: Market reaction and commentary: multiple outlets report LLY shares falling as investors re‑price competitive risk and potential slower or lower peak sales for Lilly’s oral GLP‑1; near‑term investor focus will be on comparative efficacy, launch execution, and pricing dynamics. Eli Lilly Stock Falls. Novo Nordisk Got a Wegovy Weight-Loss Pill Approved in U.S.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.